271 related articles for article (PubMed ID: 17111370)
21. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
22. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
Zhao YF; Wang CR; Wu YM; Ma SL; Ji Y; Lu YJ
Biomed Pharmacother; 2011 Jun; 65(3):151-6. PubMed ID: 21616632
[TBL] [Abstract][Full Text] [Related]
23. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
24. Melanoma differentiation-associated gene-7 protein physically associates with the double-stranded RNA-activated protein kinase PKR.
Pataer A; Vorburger SA; Chada S; Balachandran S; Barber GN; Roth JA; Hunt KK; Swisher SG
Mol Ther; 2005 May; 11(5):717-23. PubMed ID: 15851010
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.
Hotta K; Tabata M; Kiura K; Kozuki T; Hisamoto A; Katayama H; Takigawa N; Fujimoto N; Fujiwara K; Ueoka H; Tanimoto M
Oncol Rep; 2007 Feb; 17(2):313-7. PubMed ID: 17203166
[TBL] [Abstract][Full Text] [Related]
26. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Zhang J; Jia J; Zhu F; Ma X; Han B; Wei X; Tan C; Jiang Y; Chen Y
Mol Biosyst; 2012 Oct; 8(10):2645-56. PubMed ID: 22833077
[TBL] [Abstract][Full Text] [Related]
27. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Shen H; Yuan Y; Sun J; Gao W; Shu YQ
Biomed Pharmacother; 2010 Feb; 64(2):88-92. PubMed ID: 20005069
[TBL] [Abstract][Full Text] [Related]
28. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
Galetti M; Alfieri RR; Cavazzoni A; La Monica S; Bonelli M; Fumarola C; Mozzoni P; De Palma G; Andreoli R; Mutti A; Mor M; Tiseo M; Ardizzoni A; Petronini PG
Biochem Pharmacol; 2010 Jul; 80(2):179-87. PubMed ID: 20363215
[TBL] [Abstract][Full Text] [Related]
29. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
[TBL] [Abstract][Full Text] [Related]
30. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
31. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Ko JC; Wang LH; Jhan JY; Ciou SC; Hong JH; Lin ST; Lin YW
Lung Cancer; 2009 Sep; 65(3):290-8. PubMed ID: 19157634
[TBL] [Abstract][Full Text] [Related]
32. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
33. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells.
Lebedeva IV; Su ZZ; Emdad L; Kolomeyer A; Sarkar D; Kitada S; Waxman S; Reed JC; Fisher PB
Oncogene; 2007 Feb; 26(5):733-44. PubMed ID: 16924242
[TBL] [Abstract][Full Text] [Related]
34. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
[TBL] [Abstract][Full Text] [Related]
35. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
36. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Das AK; Sato M; Story MD; Peyton M; Graves R; Redpath S; Girard L; Gazdar AF; Shay JW; Minna JD; Nirodi CS
Cancer Res; 2006 Oct; 66(19):9601-8. PubMed ID: 17018617
[TBL] [Abstract][Full Text] [Related]
37. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Jänne PA
Lung Cancer; 2008 Jun; 60 Suppl 2():S3-9. PubMed ID: 18513582
[TBL] [Abstract][Full Text] [Related]
38. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
[TBL] [Abstract][Full Text] [Related]
40. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Ju L; Zhou C; Li W; Yan L
J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
